Literature DB >> 16814821

Clinical and epidemiological characteristics of yellow fever in Brazil: analysis of reported cases 1998-2002.

Suely Hiromi Tuboi1, Zouraide Guerra Antunes Costa, Pedro Fernando da Costa Vasconcelos, Douglas Hatch.   

Abstract

Yellow fever (YF), an arboviral infection of major public health importance in Brazil, is associated with high mortality and high epidemic potential. We analysed confirmed YF cases from the National Surveillance System from 1998-2002 and assessed risk factors for death among hospitalised patients. Variables assessed included age, gender, clinical signs and laboratory findings. A logistic regression model was used to identify independent predictors of death among hospitalised patients. From 1998-2002, among 2117 suspected YF cases reported to Brazil's Ministry of Health, 251 (11.9%) had confirmed YF, of whom 217 (86.5%) were hospitalised and the case fatality rate was 44.2%. Factors associated with higher mortality in univariate analysis included male gender (relative risk (RR) 1.96, 95% CI 1.17-2.28), age >40 years (RR 2.61, 95% CI 1.25-5.45), jaundice (RR 2.66, 95% CI 2.12-3.35), serum aspartate aminotransferase (AST) >1200 IU/l (RR 1.84, 95% CI 1.23-2.74), alanine aminotransferase >1500 IU/l (RR 2.09, 95% CI 1.38-3.17), total bilirubin >7.0mg/dl (RR 2.33, 95% CI 1.44-3.78), direct bilirubin >5.0mg/dl (RR 2.29, 95% CI 1.33-3.94) and blood urea nitrogen >100mg/dl (RR 5.77, 95% CI 1.43-23.22). In multivariate analysis, elevated AST and jaundice remained independently associated with higher mortality. These findings suggest that selected clinical and laboratory indicators may help clinicians recognise potentially fatal cases of YF.

Entities:  

Mesh:

Year:  2006        PMID: 16814821     DOI: 10.1016/j.trstmh.2006.04.001

Source DB:  PubMed          Journal:  Trans R Soc Trop Med Hyg        ISSN: 0035-9203            Impact factor:   2.184


  29 in total

1.  Yellow Fever: Factors Associated with Death in a Hospital of Reference in Infectious Diseases, São Paulo, Brazil, 2018.

Authors:  Ana Freitas Ribeiro; Roberta Figueiredo Cavalin; Jamal Muhamad Abdul Hamid Suleiman; Jessica Alves da Costa; Marileide Januaria de Vasconcelos; Ceila Maria Sant'Ana Málaque; Jaques Sztajnbok
Journal:  Am J Trop Med Hyg       Date:  2019-07       Impact factor: 2.345

2.  The whole iceberg: estimating the incidence of yellow fever virus infection from the number of severe cases.

Authors:  Michael A Johansson; Pedro F C Vasconcelos; J Erin Staples
Journal:  Trans R Soc Trop Med Hyg       Date:  2014-06-30       Impact factor: 2.184

Review 3.  Review of data and knowledge gaps regarding yellow fever vaccine-induced immunity and duration of protection.

Authors:  J Erin Staples; Alan D T Barrett; Annelies Wilder-Smith; Joachim Hombach
Journal:  NPJ Vaccines       Date:  2020-07-06       Impact factor: 7.344

Review 4.  The continued threat of emerging flaviviruses.

Authors:  Theodore C Pierson; Michael S Diamond
Journal:  Nat Microbiol       Date:  2020-05-04       Impact factor: 17.745

Review 5.  Efficacy and duration of immunity after yellow fever vaccination: systematic review on the need for a booster every 10 years.

Authors:  Eduardo Gotuzzo; Sergio Yactayo; Erika Córdova
Journal:  Am J Trop Med Hyg       Date:  2013-09       Impact factor: 2.345

Review 6.  Yellow Fever Virus: Diagnostics for a Persistent Arboviral Threat.

Authors:  Jesse J Waggoner; Alejandra Rojas; Benjamin A Pinsky
Journal:  J Clin Microbiol       Date:  2018-09-25       Impact factor: 5.948

7.  Efficacy of 2'-C-methylcytidine against yellow fever virus in cell culture and in a hamster model.

Authors:  Justin G Julander; Ashok K Jha; Jung-Ae Choi; Kie-Hoon Jung; Donald F Smee; John D Morrey; Chung K Chu
Journal:  Antiviral Res       Date:  2010-03-20       Impact factor: 5.970

8.  Severe Yellow Fever and Extreme Hyperferritinemia Managed with Therapeutic Plasma Exchange.

Authors:  Jaques Sztajnbok; Ceila Maria Sant'Ana Malaque; Camila Hitomi Nihei; Irene Faria Duayer; Zita Maria Leme Britto; Eduarda Gambini Beraldo; Ralcyon Francis AzevedoTeixeira
Journal:  Am J Trop Med Hyg       Date:  2019-09       Impact factor: 2.345

9.  Treatment of yellow fever virus with an adenovirus-vectored interferon, DEF201, in a hamster model.

Authors:  Justin G Julander; Jane Ennis; Jeffrey Turner; John D Morrey
Journal:  Antimicrob Agents Chemother       Date:  2011-02-07       Impact factor: 5.191

10.  Persistence of yellow fever virus-specific neutralizing antibodies after vaccination among US travellers.

Authors:  Nicole P Lindsey; Kalanthe A Horiuchi; Corey Fulton; Amanda J Panella; Olga I Kosoy; Jason O Velez; Elizabeth R Krow-Lucal; Marc Fischer; J Erin Staples
Journal:  J Travel Med       Date:  2018-01-01       Impact factor: 8.490

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.